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The biogenic amine tyramine has been reported to stimulate in vitro glucose trans­
port in adipocytes, cardiomyocytes and skeletal muscle, and to improve in vivo glu­
cose utilization in rats. These effects were dependent on amine oxidation, since they 
were blocked by inhibitors of monoamine oxidase (MAO) and semicarbazide-sensi­
tive amine oxidase (SSAO). We thus tested in this work whether a prolonged treat­
ment with tyramine could improve glucose tolerance in streptozotocin-induced dia­
betic rats. First, tyramine content of standard rodent chow was determined by 
HPLC and daily tyramine intake of contrai rats was estimated to be around 
26 µmol/kg body weight. Then, tyramine was administred during 3 weeks in strep­
tozotocin-induced diabetic rats at 29 µmol/kg by daily i.p. injection alone or togeth­
er with vanadate 0.02 µmol/kg. In another group of diabetic rats, tyramine was sub­
cutaneously delivered at 116 µmol/kg/day by osmotic minipumps. Ali tyramine 
treatments resulted in a decrease of the hyperglycemic responses to an i.p. glucose 
load. Adipocytes isolated from either untreated or treated diabetic rats were sensitive 
to the stimulation of glucose uptake by tyramine. However, diabetic animais receiv­
ing tyramine for three weeks did not recover from their hyperglycemia, hypoinsu­
linemia and glucosuria. These results show that the improvement of glucose tolerance 
induced by prolonged tyramine administration occurs in an insulin-depleted mode! 
and probably results from peripheral insulin-like actions of the oxidation of 
MAO/SSAO substrates, such as the stimulation of glucose uptake into adipocytes. 
Key words: Semicarbazide-sensitive amine oxidase, Monoamine oxidase, Diabetes, Insulin, 
Rats. 
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Amine oxidation is occuring in many 
tissues where it bas been considered as a 
way to scavenge exogenous or biogenic 
amines and to terminate the action of sev­
eral neurotransmitters (7). Two families of 
amine oxidases are involved in amine oxi­
dation: the F AD-dependent monoamine 
oxidases (MAO) and the copper-contain­
ing amine oxidase family, essentially rep­
resented by semicarbazide-sensitive amine 
oxidases (SSAO). We have recently 
reported that adipose and muscular tis­
sues, which are sensitive to insulin, 
regarding to the stimulation of glucose 
uptake, express substantial amount of 
MAO and SSAO (10). In keeping with 
this, several amines such as tyramine or 
benzylamine markedly stimulate glucose 
transport in adipocytes via their oxidation 
by MAO or SSAO (2, 9). In fact, this 
stimulation of glucose transport takes 
place in a manner that partially resembles 
that of insulin, leading to the translocation 
of the insulin-sensitive glucose trans­
porter GLUT4 to the cell surface (16). 
Other insulin-like eff ects, have been 
reported for tyramine, which is a substrate 
for both MAO and SSAO: stimulation of 
adipose differentiation (5, 8), inhibition of 
lipolysis (15), and, most importantly, in 
vivo acute improvement of glucose toler­
ance in conscious rats (10). 
The present work aimed at investigat­
ing whether prolonged administration of 
tyramine could improve the impaired glu­
cose disposai of diabetic rats. Therefore, 
we have studied the capacity of chronical­
ly administred tyramine to modify the 
hyperglycemic response induced by glu­
cose load in rats previously rendered 
hyperglycemic and insulin-deficient by 
streptozotocin injection. First of all, we 
have estimated the amount of alimentary 
tyramine daily ingested by laboratory 
rats, by determining the amount of amines 
in the standard chow with an high-
perfor-
mance liquid chromatographie (HPLC) 
method. Then, a dose approximatively 
equivalent to the estimated daily oral 
intake of tyramine, was daily i.p. injected 
during 3 weeks to streptozotocin-induced 
diabetic rats. Other groups of diabetic rats 
received vanadate at a dose ineffective on 
its own (0.02 µmol/kg), alone and in com­
bination with tyramine, since vanadate 
bas been reported to improve the insulin­
like effect of amine oxidase substrates (16) 
and the antidiabetic action of chronically 
administred benzylamine (1). A higher 
dose of tyramine (116 µmol/kg/day) was 
also chronically administred during three 
weeks via mini-osmotic pumps implanted 
in the dorsal region of streptozotocin dia­
betic rats. 
W e report here that the hyperglycemia 
provocked by i.p. glucose load was 
reduced in tyramine-treated rats, when 
compared to untreated diabetic rats, tra­
ducing an overall increased glucose uti­
lization. Accordingly, tyramine and other 
amine oxidase substrates were able, in the 
presence of vanadate, to stimulate in vitro 
glucose uptake into adipocytes of diabetic 
rats. Although the prolonged treatments 
with tyramine did not completely correct 
the troubles induced by streptozotocin, 
such as reduced body weight gain, hyper­
glycemia and hypoinsulinemia, we pro­
pose that the improvement of glucose dis­
posai by MAO/SSAO substrates may be 
useful for the treatment of glucose intoler­
ance. 
Materials and Methods 
Chemicals.-Tyramine and amines used 
as standards for HPLC calibration, colla­
genase, cytochalasin B, fatty-acid-free 
bovine serum albumin, dansyl chloride, 
and other reagents were obtained from 
Sigma-Aldrich (Saint Quentin Fallavier, 
France). 2-[l,2-3HJ-Deoxyglucose (2- 
DG, 26 Ci/mmol) was purchased from 
Perkin Elmer Life science Products 
(Boston, MA). 
HPLC analysis.- After derivatization 
with dansyl chloride, amines were sepa­
rated using a gradient elution and a 
reversed-phase HPLC method with a 
Waters HPLC system (Milford, MA, 
USA) coupled to fluorescence detection 
(Àex/em : 350/520 nm) as previously 
reported (14). A RP-C18 column (5 µm, 
200 x 2 mm, 5 µm particle size, 200 A 
porosity) (Bishoff Chromatography, 
Leonberg, D) was used to separate the 
amines at 25 °C under a linear gradient 
elution (methanol/water at 0.3 ml/min). 
Retention times and peak areas were 
acquired and processed in a Waters Mille­
nium32 workstation. Amine-containing 
solutions were prepared from rat chow as 
following: pellets were crushed (2.5 g in 
75 ml of water), mixed, and 75 ml of 0.4 M 
perchloric acid was added; the mixture 
was stirred for 30 min and centrifuged at 
3600 rpm for 5 min. Samples were filtered 
through a 0.45 µm nylon filter (Millipore) 
before automated injection. 
Animais and tissue sampling.- Male 
Wistar rats with free access to food and 
water were rendered hyperglycemic and 
insulin-deficient by single injection of 
streptozotocin ( 65 mg/kg) two weeks 
before prolonged tyramine treatments 
consisting in either daily i.p. injection of 
29 µmol/kg or implantation in the dorsal 
region of osmotic minipump delivering 
116 µmol/kg/d (Alzet, Palo Alto, CA). 
After three weeks of treament, animais 
were subjected to glucose tolerance tests. 
After sacrifice, the tissues removed were 
immediately used for adipocyte isolation 
and subsequent determinations of glucose 
uptake as previously described (4). 
Rats were fasted during 6 hours before 
the tests. Blood samples were drawen 
from tail vein of conscious animais at the 
indicated times before and after glucose 
load (i.p. bolus of 2 g/kg at time 0). Blood 
glucose was immediately determined with 
Glucotrend II glucometer (Roche Diag­
nostics, Mannheim, D), as already detailed 
(10). 
Statistical analysis.- Results are given as 
mean ± S.E.M. Statistical significance was 
assessed by use of Student's t-test. NS 
means no significant diff erence between 
the compared samples. 
Results 
Biogenic amine content of standard 
chow and daily tyramine intake in rat.­
The pellets of the control chow given to 
rat (Global rodent diet, 2016 R, Harlan, 
France), containing 16 % protein and 4 % 
fat were treated as described in Materials 
and Methods and the content of the five 
biogenic amines mostly found in food or 
in animais (14) was determined by HPLC. 
The amine content (µg/g) was (mean ± 
SEM of three different determinations): 
tyramine, 45.3 ± 1.9; spermidine, 40.9 ± 
3.2; spermine, 29.6 ± 2.3; putrescine, 14.8 
± 1.7; cadaverine 7.5 ± 0.8. Thus, tyramine 
was one of the major biogenic amines 
found in chow pellets while cadaverine 
was less abundant. Considering that Wis­
tar rats consumed, under our breeding 
conditions, approx. 20 g of pellets per day, 
the daily amount of ingested tyramine was 
estimated to be 26 µmol/kg body weight. 
We therefore decided to i.p. inject tyra­
mine at 29 µmol/kg/day in diabetic rats 
during three weeks. A fourfold larger dose 
(116 µmol/kg/day) was also tested via 
continuous s.c. administration by osmotic 
m1m-pumps. 
Effect of repeated administration of 
tyramine and vanadate on glucose toler­
ance in diabetic rats.- lntraperitoneal glu­
cose tolerance tests (IPGTT) were con­
ducted at the end of the three-week pro­
longed tyramine treatment. The hyper­
glycemic response provocked by glucose 
load was markedly reduced in the group 
of diabetic rats chronically treated with 
tyramine 29 µmol/kg than in untreated 
diabetic animals: the peak increase of 
blood glucose occuring 15-30 min after 
glucose load was f!attened (Fig. 1 ). The 
chronic treatment with 0.02 µmol/kg, 
sodium orthovanadate did not diminish 
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Fig. 1. Influence of a repeated i.p. treatment with 
tyramine and/or vanadate on glucose tolerance test in 
male type 1 diabetic rats. 
After three weeks of treatment, rats were fasted dur­
ing 6 hours before glucose Joad (2 g/kg, i.p. bolus). 
Results are given as increase over blood glucose, 
which was, at cime 0 and in mg/100 ml: 386 ± 13 for 
untreated diabetic rats (closed squares), 513 ± 33 for 
vanadate- ( closed circles ), 400 ± 28 for tyramine­
( 4 mg/kg, open triangles), and 470 ± 22 for vanadate 
plus tyramine-group (closed triangles), respectively. 
Mean ± SEM of the number of rats given in paren­
theses. Different from untreated diabetic at ''p < 0.05. 
the hyperglycemic response to IPGTT 
and was unable to improve the antihyper­
glycemic effect of chronically administred 
tyramine (Fig. 1 ). However, the daily 
administration of tyramine did not correct 
the reduced weight gain of diabetic ani­
mals since, after three weeks of treatment, 
the body weights were 221 ± 21, and 
192 ± 8 g for untreated, and tyramine­
treated diabetic rats, vs 296 ± 15 g for nor­
momoglycemic controls (n = 5, p< 0.02). 
The low dose of vanadate was without 
any influence on weight gain and the rats 
treated daily with tyramine and/or vana­
date did not exhibited a normalization of 
their elevated blood glucose (not shown). 
A higher dose of tyramine was thus tested 
alone, without combination with vana­
date. 
Influence of continuous tyramine 
administration on glucose tolerance and 
biological parameters of diabetic rats.­
The hyperglycemic response of diabetic 
rats implanted with osmotic pumps deliv­
ering tyramine at 116 µmol/kg/day is 
shown in Fig. 2. A clear-cut decrease was 
found in the area under the curve (AUC) 
of the increase in blood glucose in the rats 
treated by prolonged tyramine adminis­
tration, when compared to untreated dia­
betic rats (arbitrary units were 13.0 ± 0.1 
and 4.9 ± 0.1, n = 5, p< 0.01). According­
ly, the rats chronically treated with tyra­
mine exhibited a tendency to disminish 
their elevated fasting plasma glucose levels 
at the time of sacrifice (250.4 ± 18. 9 vs 
328.4 ± 20.2 mg/100 ml, n = 5, p< 0.05) 
without returning to the levels of normo­
glycemic contrais (65.6 ± 3.4 mg/100 ml). 
However, chronic treatment with high 
dosage of tyramine did not correct other 
defects of streptozotocin-induced dia­
betes, such as reduced body weight (not 
shown), severe hypoinsulinemia (O. 9 ± 0.4 
vs 0.7 ± 0.1 ng/ml, NS), increased plasma 
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Fig. 2. Influence of a continuous delivery of tyramine 
by osmotic pump on glucose tolerance test in diabetic 
rats. 
Male rats (6-hour fasted) received a glucose load 
(2 g/kg i.p., arrow). Blood glucose levels are given as 
increase over blood glucose, which was, at time 0: 
412 ± 46 and 415 ± 50 mg/100 ml for untreated dia­
betic ( closed squares) and tyramine-treated rats 
(116 µmol/kg/d for 3 weeks, closed triangles), 
respectively. Different from untreated diabetic at 
') < 0.05; ,,.,,p < 0.02. 
lipid peroxidation (5.1 ± 0.4 vs 4.7 ± 0.3 
µM malonyldialdehyde, NS), and 
increased urinay glucose excretion 
(267 ± 14 vs 316 ± 32 mg/hour, in treated 
and untreated diabetic rats, respectively, n 
= 5, NS). ln normoglycemic controls, 
plasma insulin, plasma malonyldialde­
hyde, and urinary glucose excretion were: 
2.8 ± 0.4 ng/ml, 2.6 ± 0.1 µM, and 0.1 ± 0.1 
mg/h, respectively (n = 5, all values differ­
ent from diabetic at p<0.001)-
Influence of chronic tyramine treat­
ment on glucose uptake into adipocytes of 
diabetic rats.- To test whether the antihy­
perglycemic effect of tyramine observed 
during IPGTT could be explained by an 
increased peripheral glucose utilization in 
severely hypoinsulinic animals, we tested 
the insulin-like effects of tyramine on glu­
cose transport in adipocytes. Table I 
shows that tyramine was able to activate 
hexose uptake in white adipocytes, even in 
the absence of vanadate. lnterestingly, the 
fold increase over basal induced by 1 mM 
tyramine or by 100 nM insulin seemed to 
be greater in treated diabetic rats than 
either untreated diabetic rats or normo­
glycemic controls. Vanadate 0.1 mM did 
not modify basal or insulin-stimulated 
uptake but potentiated the effect of tyra­
mine in all the experimental groups. 
Discussion 
T aken together, our observations show 
that tyramine administration improves 
Table 1. Stimulation of glucose uptake (increase over basal uptake) by insu/in , tyramine and vanadate in 
adipocytes from contrai or diabetic rats. 
Group: 
lnsulin 100 nM 
Tyramine 1 mM 
Vanadate 0.1 mM 
Vanadate + insulin 
Vanadate + tyramine 
normoglycemic 
8.2 ± 1.1 
2.1 ± 0.2 
1.3 ± 0.2 
8.2 ± 1.0 
7.1±1.0 
untreated 
10.2 ± 1.4 
2.5 ± 0.4 
1.0 ± 0.1 
11.6 ± 1.8 
7.3 ± 1.9 
Diabetics 
tyramine-treated 
14.9 ± 2.9 
3.1 ± 0.9 
1.0 ± 0.3 
11.9 ± 3.6 
9.3 ± 4.0 
Basal 2-DG uptake was 1.06 ± 0.17, 1.33 ± 0.27, and 1.35 ± 0.36 nmoles of 2-deoxyglucose/100 mg of 
lipids/1 O min in normoglycemic, untreated and tyramine-treated diabetics, respectively (n = 5, NS). 
Mean ± S.E.M. of live different determinations. 
glucose tolerance in diabetic, insulin­
depleted rats, The antihyperglycemic 
properties of tyramine are likely the con­
sequence of a stimulation of hexose 
uptake in insulin-sensitive tissues, Even 
though we did not measure the variations 
of plasma insulin during IPGTT in the 
streptozotocin-treated rats, it can be sup­
posed that an indirect effect via stimula­
tion of insulin secretion was not involved 
in the antihyperglycemic action of tyra­
mine. A stimulation of glucose transport 
in peripheral tissues by tyramine, as evi­
denced in vitro on fat cells, is therefore 
expected to occur under in vivo condi­
tions. This insulin-like effect could be suf­
ficient to explain the increase in glucose 
tolerance, although an inhibition of hepat­
ic glucose output or a stimulation of 
insulin-secretion induced by tyramine 
could not be excluded since there is very 
high expression of MAO in liver (10) and 
since the role of MAO in insulin secretion 
is still unsolved in the endocrine pancreas 
(11 ). lt is important to note that the tyra­
mine-induced stimulation of glucose tran­
port we report here in adipocytes from 
diabetic rats has been previously oberved 
also in cardiomyocytes and skeletal mus­
cle from control rats (10). Tyramine could 
therefore be suspected to lower hyper­
glycemic response to glucose load by 
stimulating glucose uptake in all the 
insulin-sensitive tissues. Moreover, inhi­
bition of lipolysis is another insulin-like 
action of tyramine found on adipose cells 
(15) that may facilitate glucose disposai.
The improvement of glucose disposai 
induced by a chronic treatment with tyra­
mine is in perfect agreement with our pre­
vious studies in which an acute adminis­
tration of tyramine, just before a glucose 
load, was found to exert antihyper­
glycemic properties (10). The present data 
also permit to assess that insulin-like 
effect of tyramine on glucose diposal per­
sists after repeated administration. This 
assessment, together with the blockade of 
tyramine effects by MAO and SSAO 
inhibitors (10), led to propose that the 
effect of tyramine is not a receptor-medi­
ated one, which could had been much 
more prone to desensitization, but is more 
likely a consequence of its metabolism by 
detoxifying enzymes. 
The role of vanadate remains unclear 
since it was able to potentiate the acute 
eff ect of tyramine on the in vitro mode], 
but not the chronic effect of the biogenic 
amine when tested in vivo. Although both 
doses of vanadate were ineff ective in 
IPGTT or in hexose uptake assays, they 
were peraphs not equivalent, when com­
pared to the respective tresholds of the 
diverse insulin mimicking actions of this 
transition metal. ln fact, we have already 
reported that an i.p. dose of vanadate at 
25 µmol/kg is poorly effective in reducing 
per se the hyperglycemic response to 
IPGTT in rats. The daily dosage used for 
vanadate treatment in the present study 
(0.02 µmol/kg) can therefore be consid­
ered as being around one thousand fold 
lower than the treshold for acute in vivo 
antidiabetic eff ects of vanadate. Regarding 
stimulation of glucose uptake into rat 
adipocytes, the dose used to potentiate 
tyramine effect (0.1 mM) corresponded to 
the treshold for vanadate in our as well as 
in other studies ( 6 ). Therefore, the obser­
vation of a synergism between tyramine 
and vanadate only in isolated adipocytes, 
but not in vivo, could be explained by the 
fact that, even perhaps cumulative, only 
very low doses of vanadate were used for 
in vivo chronic administration. 
lnstead of increasing vanadate concen­
tration we chosen to increase tyramine 
dosage. Since it has been previously 
reported that, at the lower dose tested 
( 4 mg/kg), an iv. bolus of tyramine 
induced a transient hypertensive effect 
that lasted less than 10 min in anaes­
thetized rats ( 10 ), we used a diff erent 
mode of administration: continous subcu­
taneous delivery via osmotic minipumps. 
With this mode of administration, we did 
not observe any behavioural change in the 
treated rats. It is important to note that 
both doses of tyramine tested in this study 
( 4 and 16 mg/kg) were largely lower than 
the oral dose of 87 mg/kg reported to elic­
it an increase in blood pressure of 30 mm 
Hg in rat, which is a reference for clinical 
risk treshold (3). Moreover, the determi­
nation by HPLC of tyramine content in 
rodent chow allowed to make, at least to 
our knowledge, the first reported estima­
tion of the daily tyramine intake of a lab­
oratory rat: 26 µmol/kg. This corresponds 
to approx 1 mg of tyramine ingested/day 
by a rat of 250 g. Such an amount is found 
in many foods and beverages: for instance, 
the amount of tyramine contained in a 
liter of wine is 0.2-6 mg/1 (13). On the 
basis of our study, one can consider that it 
is sufficient to increase by two- to eight­
fold the spontaneous alimentary tyramine 
intake to obtain a significant effect on glu­
cose disposai. Indeed, the oral ingestion of 
tyramine led to an important, but not yet 
well defined, intestinal degradation. 
Therefore 29 µmoles of i.p. injected tyra­
mine led to an amount of biogenic amine 
in the peripheral tissues, including adipose 
depots, much more greater than brought 
by the dietary amine. In man, endogenous 
plasma tyramine concentration is around 
10 nM under fasting conditions ( 4 ). This 
trace amount makes unlikely that only 
tyramine participates in a putative inter­
play between dietary amines and glucose 
metabolism. However, tyramine and 
other dietary amines share insulin-mimic­
king properties and we propose that their 
effects could be cumulative under in vivo
conditions rather than competitive until 
the activity of amine oxidases in adipose 
tissues or in other peripheral organs does 
not reach saturation. Thus, it cannot be 
excluded that it is possible to reach with 
an oral load a sufficient amount of dietary 
amines capable to interfere with glucose 
metabolism as observed here with i.p. or 
s.c. administred tyramine. To support this
view, it can be mentionned that mice fed a
diet based on oat variety with a low
polyamine content develop smaller lym­
phosarcoma tumours than animais fed a
standard diet (12). This shows that
changes in the amount of dietary amines
or polyamines can influence the organism
maybe via changes in the absorbed
amount of amines, escaping from degra­
dation by the intestinal barrier. At the
end, the stimulating effects of chonic tyra­
mine challenge on glucose disposai we
observed in a model of type I diabetes led
us to propose that amine oxidation can
constitute a rationale for therapeutic
approach of diseases linked to glucose
intolerance.
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Se ha descrito que la amina biogénica tira­
mina estimula in vitro el transporte de glucosa 
en adipocitos, cardiomiocitos y musculo 
esquelético y mejora la utilizaci6n de glucosa 
en la rata. Estos efectos son dependientes de la 
oxidaci6n de la tiramina por la monoamino­
oxidasa (MAO) y la amino-oxidasa sensible a 
semicarbazida (SSAO). En este trabajo, se 
estudia si un tratamiento cr6nico con tiramina 
aumenta la tolerancia a la glucosa en ratas dia­
béticas por estroptozotocina. El contenido en 
tiramina del alimento estandar para roedores se 
determin6 por HPLC y se estim6 que el con­
sumo diario de tiramina en ratas control era de 
unos 26 µmol/kg de peso corporal. Por tanto, 
se administr6 diariamente durante 3 semanas 
tiramina por vfa i.p. a la dosis de 29 µmol/kg, 
sola o con vanadato 0.02 µmol/kg a ratas dia­
béticas por estroptozotocina. Otro grupo reci­
bi6 tiramina por vfa subcutanea mediante 
minibombas osm6ticas liberando 116 µmol/ 
kg/dfa. Los tratamientos con tiramina han 
inducido disminuci6n de las respuestas hiper­
glucemiantes a la sobrecarga de glucosa. En 
adipocitos aislados de ratas diabéticas, tratadas 
o no, la tiramina estimula el transporte de glu­
cosa. Sin embargo, los animales diabéticos tra­
tados con tiramina no se recuperaron de su
hiperglucemia, hipoinsulinemia y glucosuria.
Nuestros datos sugieren que la mejora de la
tolerancia a la glucosa inducida por el trata­
miento cr6nico con tiramina se observa en un
modelo deficiente en insulina y probablemente
se debe a acciones insulinomiméticas. Esta
tambien indica que la administraci6n de sustra­
tos de MAO/SSAO podrfa constituir la base
de nuevos tratamientos para mejorar la utiliza­
ci6n de la glucosa.
Palabras clave: Amino-oxidasa sensible a semicar­
bazide, Monoamino-oxidasa, Diabetes, Insulina, 
Rata. 
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